CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2017	Oct. 01, 2016
Cash Flows from Operating Activities:
Net income	$ 40,239	$ 9,479
Non-cash items:
Depreciation and amortization	43,986	45,253
Gain on divestiture	(8,000)	0
Stock-based compensation expense	4,199	4,235
Provision for losses on accounts receivable and inventory	688	6,902
Impairment of assets	0	2,505
Other non-cash operating activities	312	(1,241)
Change in operating assets and liabilities:
Change in accounts receivable	10,739	6,807
Change in inventories	7,284	(12,661)
Change in prepaid income taxes	776	(324)
Change in other assets and other liabilities	3,920	2,836
Change in accounts payable and accrued expenses	(6,815)	6,169
Net cash provided by operating activities	97,328	69,960
Cash Flows from Investing Activities:
Capital expenditures	(29,125)	(41,624)
Proceeds from divestiture	9,000	0
Proceeds from sale of property, plant and equipment	1,346	197
Net cash used in investing activities	(18,779)	(41,427)
Cash Flows from Financing Activities:
Repayment of term loan borrowings	(28,455)	(18,970)
Proceeds from employee stock purchase plan	1,622	1,979
Proceeds from exercise of stock options	10,120	13,532
Net increase (decrease) in short-term loans	417	(1,116)
Net cash used in financing activities	(16,296)	(4,575)
Effect of exchange rates on cash and cash equivalents	1,805	(211)
Net Change in Cash and Cash Equivalents	64,058	23,747
Cash and Cash Equivalents at Beginning of Period	139,564	115,123
Cash and Cash Equivalents at End of Period	203,622	138,870
Supplemental Disclosures of Cash Flow Information:
Interest paid	3,768	4,118
Income taxes paid	5,449	3,867
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 3,965	$ 3,477